(IMCR) Immunocore Holdings plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IMCR) Immunocore Holdings plc Complete Analysis Pack
Actionable Strategy Starts Here
This Immunocore Holdings plc BCG Matrix helps you see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. What you see on this page is a real preview of the actual report content, not just a teaser. Buy the full version to get the complete ready-to-use analysis instantly.
Stars
KIMMTRAK growth franchise
KIMMTRAK was Immunocore Holdings plc’s only marketed product at year-end 2025 and the core growth engine. It is the first approved therapy for HLA-A*02:01-positive unresectable or metastatic uveal melanoma, giving it a first-mover edge in a small but protected niche. That combination of rare-disease focus, label leadership, and expanding physician uptake fits a Star profile.
ImmTAC platform leadership
ImmTAC gives Immunocore Holdings plc a real edge in the T-cell receptor bispecific space: it is one of the few commercial-stage TCR companies with a validated human drug, KIMMTRAK, the first and only approved TCR therapy. That proof of concept lowers scientific risk and helps pull in development capital and partners. The platform’s 2025 value lies in credibility, not just pipeline breadth.
Uveal melanoma label expansion
KIMMTRAK remains the only approved therapy for HLA-A*02:01-positive unresectable or metastatic uveal melanoma, and IMCgp100-202 showed 21.7-month median OS vs 16.0 months for investigator choice. Immunocore Holdings plc’s upside is a move into earlier-line and adjuvant use, where the addressable pool would expand fast. That makes this a Star: category leader, strong clinical pull, and clear label-expansion runway.
Global commercialization footprint
Immunocore Holdings plc has turned KIMMTRAK into a real commercial platform, with sales reach across the US and other major markets by end-2025. That matters because KIMMTRAK’s 2025 launch base can now scale with lower incremental cost, so the footprint is becoming an asset, not just SG&A drag. Stronger field coverage also helps convert clinical wins into repeat prescriptions and stickier market share.
- US-led commercial engine
- Major-market expansion in 2025
- Better conversion, lower marginal cost
Precision oncology first-mover position
Immunocore Holdings plc has a first-mover edge in TCR-based precision oncology, targeting intracellular cancer antigens that most antibody drugs cannot reach. That puts its oncology franchise in a fast-growing precision medicine niche, with a differentiated platform and early commercial proof from tebentafusp, the first approved T-cell receptor therapy.
- Targets intracellular antigens
- First approved TCR therapy
- Precision oncology growth tailwind
KIMMTRAK Drives Immunocore’s Growth With Clear Survival Advantage
KIMMTRAK is Immunocore Holdings plc’s Star: the only approved TCR therapy and the only approved option for HLA-A*02:01-positive unresectable or metastatic uveal melanoma. The IMCgp100-202 trial showed 21.7-month median OS versus 16.0 months with investigator choice, supporting label expansion and durable demand.
| Star driver | 2025/2026 data |
|---|---|
| KIMMTRAK | Only marketed product |
| OS benefit | 21.7 vs 16.0 months |
| Platform | First approved TCR therapy |
What is included in the product
Detailed Word Document
BCG Matrix overview of Immunocore Holdings plc’s portfolio, highlighting Stars, Cash Cows, Question Marks, and Dogs with strategic actions.
Editable Excel File
Quick BCG view of Immunocore Holdings plc to spot growth, cash, and drag fast.
Reference Sources
Provides a clear source trail for Immunocore Holdings plc, strengthening credibility and helping stakeholders verify key assumptions fast.
Cash Cows
KIMMTRAK approved sales base
By FY2025, KIMMTRAK was Immunocore Holdings plc's only marketed drug and the only clear recurring revenue stream, so it fits the Cash Cows box. The asset serves metastatic uveal melanoma patients with repeat dosing, which makes it a steady, branded sales base. In 2025, that single-product franchise carried the company's commercial income and funded the rest of the pipeline.
Uveal melanoma market leadership
KIMMTRAK (tebentafusp) is Immunocore Holdings plc’s strongest asset in its approved uveal melanoma niche. Uveal melanoma is rare, at about 5–7 cases per million people a year in the U.S., so the market is small and relatively mature. That makes high share in a low-growth setting the classic Cash Cow profile, with KIMMTRAK doing the heavy lifting in revenue.
Established medical affairs spend
By FY2025, KIMMTRAK was an established launch, approved in 2022, so medical affairs spend should be steadier than for a new pipeline asset. That lowers promotional burn and supports better operating leverage. The cash-cow logic is simple: keep the brand supported, but with a much lighter cash drain than at launch.
Commercial manufacturing for KIMMTRAK
KIMMTRAK is already in commercial production, so Immunocore Holdings plc can spread fixed plant, QA, and supply-chain costs across a bigger treated base. That helped KIMMTRAK net product revenue reach $292.8 million in 2024, up 42% year over year, showing a more efficient franchise as volume rises.
With manufacturing know-how already embedded, each extra patient should lift gross leverage more than early-stage assets.
- Marketed brand; no launch buildout
- Fixed costs spread over growth
- 2024 KIMMTRAK revenue: $292.8m
- Efficiency improves as patients rise
Revenue concentration in one brand
Immunocore Holdings plc still depends on KIMMTRAK, its only marketed product, so most revenue and cash flow sit in one brand. That makes concentration a real risk, but it also gives the company one clear profit pool to protect and scale, which is why this segment fits the Cash Cow label in BCG terms.
At the same time, KIMMTRAK reached a bigger commercial base by 2025, with growth driven by metastatic uveal melanoma demand. The upside is clear; the downside is that any slowdown, pricing pressure, or label setback would hit the whole model fast.
- One product drives the business.
- Cash flow is easier to manage.
- Concentration keeps risk high.
- BCG fit: closest to a Cash Cow.
KIMMTRAK: Immunocore’s Cash Cow Keeps Growing
KIMMTRAK is Immunocore Holdings plc’s only marketed product, so by FY2025 it still carried nearly all commercial cash generation and fits the Cash Cow box. In 2024, net product revenue reached $292.8 million, up 42% year over year, showing a mature but still expanding base.
Uveal melanoma is rare at about 5–7 cases per million people a year in the U.S., so growth is limited and the value lies in defending share. That makes KIMMTRAK a stable, low-growth franchise with steady repeat dosing and lower launch spend.
| Metric | Data |
|---|---|
| Marketed products | 1 |
| FY2024 KIMMTRAK revenue | $292.8m |
| YoY growth | 42% |
| Uveal melanoma incidence | 5–7 per million |
Full Version Awaits
Immunocore Holdings plc Reference Sources
The Immunocore Holdings plc BCG Matrix preview you see is the exact same document you’ll receive after purchase. No mockups, no watered-down version—just the full, professionally formatted report. It’s ready to download, review, and use right away for analysis or presentation.
Dogs
No second marketed brand
As of FY2025, Immunocore Holdings plc still had only one marketed product, KIMMTRAK, and no disclosed second commercial brand. That leaves no clear low-share, low-growth legacy product to classify as a Dog. So the portfolio remains highly concentrated in one franchise, with commercial results still tied mainly to KIMMTRAK.
No mature infectious-disease revenue asset
Immunocore Holdings plc’s hepatitis B and HIV programs are still in development, so they generate no commercial revenue and hold no market share yet. That means they are not true Dogs in the classic BCG sense, because they do not drag on cash from a mature, low-share product; they are simply pre-revenue assets. The key risk is spend without payback, since these programs still need clinical data, regulatory steps, and time before they can add cash.
No approved autoimmune product
Immunocore Holdings plc has no approved autoimmune product yet, so this BCG "Dog" call does not fit: the autoimmune candidates are still pre-revenue and need proof of concept before they can earn share. In FY2025, they remain a pipeline option, not a sales driver. Until approval and launch data arrive, they stay early-stage, not a true Dog.
No disclosed legacy divestiture
Immunocore Holdings plc has no disclosed legacy divestiture, so the Dogs bucket looks thin. The Company is still a focused single-platform biotech, with KIMMTRAK as the main revenue engine; in 2024, product revenue was about $319 million, leaving little sign of a low-value inherited franchise to prune.
- No major legacy brand to sell
- Revenue tied to one core platform
- Dogs risk remains limited
Effectively empty Dog quadrant
Immunocore Holdings plc has an effectively empty Dog quadrant because the public portfolio does not show a mature asset with both weak growth and weak share. KIMMTRAK is still the only clear commercial product, while most other programs remain experimental, so they fit Question Mark or Star, not Dog.
In FY2025, that means the portfolio is still centered on one marketed therapy and early-stage pipeline bets, not on aging low-value products. So the Dog box stays largely unused rather than filled.
- No mature weak-share asset
- Most non-KIMMTRAK programs are experimental
- Dog quadrant stays essentially empty
Immunocore Has No Real Dogs in FY2025
Immunocore Holdings plc has no true Dogs in FY2025: KIMMTRAK is still the only marketed product, and non-core programs are pre-revenue. With product revenue at about $319 million in 2024 and no disclosed legacy low-share brand, the Dog box stays thin. The main risk is pipeline spend, not a weak mature asset.
| Dog check | FY2025 signal |
|---|---|
| Marketed products | 1 |
| Product revenue | About $319m |
| Legacy weak-share asset | No disclosed |
| Dog quadrant | Essentially empty |
Question Marks
IMC-C103C Phase I/II
IMC-C103C is still a Question Mark in Immunocore Holdings plc’s BCG matrix: it is in Phase I/II across solid tumors, so it has high upside but no proven market share yet. In 2025, Immunocore reported continued R&D spend of over $200 million, showing this program is still a cash-heavy bet. If efficacy holds, it could become a Star.
IMC-F106C Phase I/II
IMC-F106C is still a Question Mark in Immunocore Holdings plc's BCG mix: it remains in Phase I/II dose-escalation, with early testing across lung, ovarian, melanoma, and breast cancer. The addressable solid-tumor market is huge, but commercial proof is still missing, so risk stays high. Until response and safety data mature, its value is optionality, not revenue.
IMC-I109V Phase I/II
IMC-I109V Phase I/II is still in early clinical development for chronic hepatitis B, so Immunocore Holdings plc has no market share in HBV yet. HBV remains a huge target, with about 254 million people living with chronic infection worldwide, but the program is not commercial today. That mix of high upside and very low current position fits a Question Mark in the BCG Matrix.
IMC-M113V preclinical HIV
IMC-M113V preclinical HIV is a classic Question Mark: it is still outside the clinic, so Immunocore Holdings plc has only preclinical proof so far. That matters because HIV remains huge, with about 39.9 million people living with HIV worldwide in 2023, but this program still carries high failure risk and no human efficacy data.
- Huge market, early science
- Only preclinical evidence
- High upside, high risk
Autoimmune precision immunosuppression pipeline
Autoimmune precision immunosuppression is a Question Mark: autoimmune diseases affect about 5% of people worldwide, so the market is large, but Immunocore has not disclosed detailed assets or late-stage data. These programs are still early, so they need heavy R&D spend and clinical proof before they can move toward Star territory. For now, they are a funded option, not a near-term revenue driver.
- Large unmet need, early pipeline
- Undisclosed assets limit visibility
- High spend before value inflects
Immunocore’s High-Risk Question Marks: Big Bets, Little Proof
Question Marks in Immunocore Holdings plc are early, high-risk bets with no clear market share yet. IMC-C103C, IMC-F106C, IMC-I109V, IMC-M113V, and autoimmune precision immunosuppression all sit in early-stage or preclinical testing, while 2025 R&D spend stayed above $200 million. Big markets, but proof is still missing.
| Program | Stage | BCG role |
|---|---|---|
| IMC-C103C | Phase I/II | Question Mark |
| IMC-M113V | Preclinical | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.